Multiple sclerosis therapeutic strategies: Start safe and effective, reassess early, and escalate if necessary

Neurology: Clinical Practice

Volumn 1, Issue 1, 2011, Pages 69-72

  Naismith, Robert T ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; GLATIRAMER; INTERFERON; NATALIZUMAB;

ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; JC VIRUS; MULTIPLE SCLEROSIS; PATIENT COUNSELING; PATIENT MONITORING; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE;

EID: 84876510633     PISSN: 21630402     EISSN: 21630933     Source Type: Journal    
DOI: 10.1212/CPJ.0b013e31823cc2b0     Document Type: Article

References (5)

1. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144-1151.
2. Klawiter EC, Cross AH, Naismith RT. The present efficacy of multiple sclerosis therapeutics: is the new 66% just the old 33%? Neurology 2009;73:984-990.
3. Lucchinetti CF, Gavrilova RH, Metz I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 2008;131:1759-1775.
4. Comi G. Induction vs escalating therapy in multiple sclerosis: practical implications. Neurol Sci 2008;29:253-255.
5. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68:295-303.